Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
57.2M
-
Number of holders
-
92
-
Total 13F shares, excl. options
-
32.1M
-
Shares change
-
+1.36M
-
Total reported value, excl. options
-
$108M
-
Value change
-
+$4.41M
-
Put/Call ratio
-
19.36
-
Number of buys
-
48
-
Number of sells
-
-37
-
Price
-
$3.35
Significant Holders of Design Therapeutics, Inc. - Common Stock (DSGN) as of Q2 2024
106 filings reported holding DSGN - Design Therapeutics, Inc. - Common Stock as of Q2 2024.
Design Therapeutics, Inc. - Common Stock (DSGN) has 92 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 32.1M shares
of 57.2M outstanding shares and own 56.15% of the company stock.
Largest 10 shareholders include SR One Capital Management, LP (6.53M shares), Logos Global Management LP (5.03M shares), BlackRock Inc. (2.3M shares), BAKER BROS. ADVISORS LP (1.7M shares), TANG CAPITAL MANAGEMENT LLC (1.48M shares), VANGUARD GROUP INC (1.3M shares), Almitas Capital LLC (1.25M shares), Frazier Life Sciences Management, L.P. (1.2M shares), Point72 Asset Management, L.P. (991K shares), and GEODE CAPITAL MANAGEMENT, LLC (708K shares).
This table shows the top 92 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.